Market cap
$3,752 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
9.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -95.34 | -119.57 | -245.62 | -240.25 |
| Net Profit | 19.14 | -95.27 | -211.75 | -273.45 | -254.41 |
| EPS | 19.38 | -88.90 | -204.00 | -246.67 | -238.19 |
| Book Value | -- | -- | -29.10 | 43.49 | 10.83 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -513,709.00 | -- | -- | -- |
| Net Margin
| -- | -6,712.23 | -- | -- | -- |
| Return on equity
| -33.34 | -32.87 | -102.12 | -47.34 | -17.90 |
| Return on Capital
| -33.25 | -32.78 | -- | -47.30 | -17.86 |
| Return on Assets
| -31.17 | -30.67 | -71.72 | -44.29 | -17.22 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
-47.30
|
-17.86
|
-34.60
|
-39.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-102.12
Lower than Peers by 61.72
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-102.12
|
-47.34
|
-17.90
|
-34.79
|
-39.67
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-71.72
Lower than Peers by 40.74
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-71.72
|
-44.29
|
-17.22
|
-31.99
|
-36.32
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
--
|
--
|
--
|
-5,598.94
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
--
|
--
|
--
|
-1.00
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-119.57
Lower than Peers by 118.77
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-119.57
|
-227.28
|
-8.97
|
-46.53
|
-25.17
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-211.75
Lower than Peers by 204.45
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-211.75
|
-227.05
|
-28.02
|
-24.73
|
-25.24
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-204.00
Lower than Peers by 218.65
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-204.00
|
-2.19
|
-0.15
|
0.05
|
-0.26
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-50.34
Lower than Peers by 40.17
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-50.34
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
0.00
|
0.00
|
0.00
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.72
Lower than Peers by 1.09
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
4.72
|
9.33
|
33.09
|
19.19
|
7.61
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
4.72
Lower than Peers by 0.98
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
4.72
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-66,848.50
Lower than Peers by 66,846.41
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-66,848.50
|
-6,421.13
|
-1,168.82
|
-1,145.76
|
-1,166.24
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
26,721.72
|
9,144.45
|
10,032.49
|
6,258.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
-11.15
|
-40.75
|
-21.69
|
-10.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
9.67
Higher than Peers by 4.49
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
9.67
|
6.28
|
5.09
|
5.35
|
4.95
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-71.64
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
-71.64
|
-9.20
|
-32.68
|
-14.90
|
-8.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3,752
Higher than Peers by 3,606
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
3,752
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|